Spots Global Cancer Trial Database for Metformin With Standard Taxotere and Prednisone in the Treatment of Castration Resistant Prostate Cancer
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Metformin With Standard Taxotere and Prednisone in the Treatment of Castration Resistant Prostate Cancer
Official Title: Metformin With Standard Taxotere and Prednisone in the Treatment of Castration Resistant Prostate Cancer
Study ID: NCT01478308
Conditions
Study Description
Brief Summary: This study is being conducted to determine the effectiveness of standard 3 weekly treatments using docetaxel and prednisone with metformin in patients with castration-resistant metastatic prostate cancer. It is also being conducted to determine the levels of toxicity of metformin when added to every 3 weekly docetaxel treatments in patients with endocrine resistent, metastatic prostate cancer.
Detailed Description: This is a single-arm, non-randomized Phase II trial of docetaxel given every 3 weeks with metformin twice daily and Prednisone twice daily. The study duration of this trial is open ended. The patient would take the metformin only for as long as they are treated with docetaxel.
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: MALE
Healthy Volunteers: No
Locations
Contact Details
Name: Richard Lauer, MD
Affiliation: University of New Mexico Cancer Center
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
